Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

计划入组 576 人 · 首次发布于 2026 年 5 月 18 日

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

计划入组 561 人 · 首次发布于 2025 年 6 月 5 日

Ciracigene golparvovec

Lenadogene nolparvovec

Timrepigene emparvovec

REGENXBIO Advances Gene Therapy to Pivotal Phase IIb/III Trial for Diabetic Retinopathy

REGENXBIO Appoints Greg Ciongoli to Board of Directors as It Prepares for Commercial Launch

REGENXBIO and AbbVie Dose First Patient in Phase IIb/III NAAVIGATE Trial of One-Time Gene Therapy Sura-vec for Diabetic Retinopathy